许继伟;宋旋;梁伟姿;杨英;

• 1:天津大学生命科学学院

摘要(Abstract)：

艾滋病全称获得性免疫缺陷综合征(acquired immunodeficiency syndrome,AIDS),是由人免疫缺陷病毒(human immunodeficiency virus,HIV)感染引起的,已成为全球性健康难题。HIV通过攻击CD4⁺ T细胞而破坏机体的免疫系统,且该病毒易发生突变,使相应疫苗的设计更加困难,诱导中和抗体产生的同时激发机体的细胞免疫将成为开发有效艾滋病疫苗的新思路。本文对HIV的结构特点及疫苗设计、艾滋病疫苗诱导的细胞及体液免疫作一综述,并对该疫苗的开发前景进行展望。

关键词(KeyWords)： 艾滋病;疫苗

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 许继伟;宋旋;梁伟姿;杨英;

DOI: 10.13200/j.cnki.cjb.001235

参考文献(References)：

• [1]JIA Z,WANG L,CHEN R Y,et al.Tracking the evolution of HIV/AIDS in China from 1989-2009 to inform future prevention and control efforts[J].PLo S One,2011,6(10):e25671.doi:10.1371/journal.pone.0025671.
• [2]SPICER N,BOGDAN D,BRUGHA R,et al.'It's risky to walk in the city with syringes':understanding access to HIV/AIDS services for injecting drug users in the former Soviet Union countries of Ukraine and Kyrgyzstan[J].Global Health,2011,7(1):22-36.
• [3]FREY G,PENG H,RITS-VOLLOCH S,et al.A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies[J].Proc Natl Acad Sci USA,2008,105(10):3739-3744.
• [4]CHERTOVA E,BESS J W Jr,CRISE B J,et al.Envelope glycoprotein incorporation,not shedding of surface envelope glycoprotein(gp120/SU),Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus[J].J Virol,2002,76(11):5315-5325.
• [5]HAYNES B F,GILBERT P B,MCELRATH M J,et al.Immune-correlates analysis of an HIV-1 vaccine efficacy trial[J].N Engl J Med,2012,366(14):1275-1286.
• [6]SAGAR M,WU X,LEE S,et al.Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection,and these modifications affect antibody neutralization sensitivity[J].J Virol,2006,80(19):9586-9598.
• [7]WU X,ZHOU T,O'DELL S,et al.Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment[J].J Virol,2009,83(21):10892-10907.
• [8]HESSELL A J,RAKASZ E G,POIGNARD P,et al.Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers[J].PLo S Pathog,2009,5(5):e1000433.doi:10.1371/journal.ppat.1000433.
• [9]ZWICK M B,JENSEN R,CHURCH S,et al.Anti-human immunodeficiency virus type 1(HIV-1)antibodies 2F5 and 4E10require surprisingly few crucial residues in the membraneproximal external region of glycoprotein gp41 to neutralize HIV-1[J].J Virol,2005,79(2):1252-1261.
• [10]RUPRECHT C R,KRARUP A,REYNELL L,et al.MPERspecific antibodies induce gp120 shedding and irreversibly neutralize HIV-1[J].J Exp Med,2011,208(3):439-454.
• [11]KAMDEM TOUKAM D,TENBUSCH M,STANG A,et al.Targeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus[J].PLo S One,2012,7(5):e38068.doi:10.1371/journal.pone.0038068.
• [12]PANCERA M,MCLELLAN J S,WU X,et al.Crystal structure of PG16 and chimeric dissection with somatically related PG9:structure-function analysis of two quaternaryspecific antibodies that effectively neutralize HIV-1[J].J Virol,2010,84(16):8098-8110.
• [13]DOORES K J,BURTON D R.Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16[J].J Virol,2010,84(20):10510-10521.
• [14]WALKER L M,HUBER M,DOORES K J,et al.Broad neutralization coverage of HIV by multiple highly potent antibodies[J].Nature,2011,477(7365):466-470.
• [15]OFEK G,MCKEE K,YANG Y,et al.Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region[J].J Virol,2010,84(6):2955-2962.
• [16]KLEIN F,DISKIN R,SCHEID J F,et al.Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization[J].Cell,2013,153(1):126-138.
• [17]ALAM S M,MORELLI M,DENNISON S M,et al.Role of HIV membrane in neutralization by two broadly neutralizing antibodies[J].Proc Natl Acad Sci USA,2009,106(48):20234-20239.
• [18]BURTON D R,AHMED R,BAROUCH D H,et al.A blueprint for HIV vaccine discovery[J].Cell Host Microbe,2012,12(4):396-407.
• [19]HAYNES B F,KELSOE G,HARRISON S C,et al.B-celllineage immunogen design in vaccine development with HIV-1as a case study[J].Nat Biotechnol,2012,30(5):423-433.
• [20]SANDERS R W,DERKING R,CUPO A,et al.A nextgeneration cleaved,soluble HIV-1 Env trimer,BG505 SOSIP.664 gp140,expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies[J].PLo S Pathog,2013,9(9):e1003618.doi:10.1371/journal.ppat.1003618.
• [21]SANDERS R W,VAN GILS M J,DERKING R,et al.HIV-1vaccines.HIV-1 neutralizing antibodies induced by native-like envelope trimers[J].Science,2015,349(6244):aac4223.
• [22]RINGE R P,YASMEEN A,OZOROWSKI G,et al.Influences on the design and purification of soluble,recombinant nativelike HIV-1 envelope glycoprotein trimers[J].J Virol,2015,89(23):12189-12210.
• [23]JARDINE J G,OTA T,SOK D,et al.HIV-1 vaccines.Priming a broadly neutralizing antibody response to HIV-1using a germline-targeting immunogen[J].Science,2015,349(6244):156-161.
• [24]DOSENOVIC P,VON BOEHMER L,ESCOLANO A,et al.Immunization for HIV-1 broadly neutralizing antibodies in human Ig knock in mice[J].Cell,2015,161(7):1505-1515.
• [25]HANSEN S G,PIATAK M Jr,VENTURA A B,et al.Immune clearance of highly pathogenic SIV infection[J].Nature,2013,502(7469):100-104.
• [26]LIFSON J D,ROSSIO J L,PIATAK M Jr,et al.Role of CD8(+)lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment[J].J Virol,2001,75(21):10187-10199.
• [27]RERKS-NGARM S,PITISUTTITHUM P,NITAYAPHAN S,et al.Vaccination with ALVAC and AIDSVAX to prevent HIV-1infection in Thailand[J].N Engl J Med,2009,361(23):2209-2220.
• [28]HAMMER S M,SOBIESZCZYK M E,JANES H,et al.Efficacy trial of a DNA/r Ad5 HIV-1 preventive vaccine[J].N Engl J Med,2013,369(22):2083-2092.
• [29]AMARA R R,SMITH J M,STAPRANS S I,et al.Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine[J].J Virol,2002,76(12):6138-6146.